PTO/SB 91 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no passins are required to respond to a collection of information unless it displays a valid OMB control number.

(Also PTO Form 3.76)

DEPOSIT ACCOUNT ORDER FORM

DATE	-	200	
7	awary	24,	200

This form is to be used only for orders, the costs of which are to be charged against United States Patent and Trademark Office Deposit Accounts. IT MUST NOT BE USED FOR orders when payment is made by cash, checks, credit cards, or coupons. In addition, it should not be used for ordering printed copies of U.S. Patents. Use a separate form for each of the following types of service ordered: Recordings, Reproductions, Title Reports, Translations. Mail to: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Reports, Translations. Mail to: Commissioner of					
NAME AND ADDRESS FOR DEPOSITOR	FOR OFFICE USE ONLY				
Melissa A. Shaw Bayer Corporation 800 Dwight Way P. O. Box 1986 Berkeley, CA 94701					
ACCOUNT NUMBER	YOUR ORDER NUMB	ER			
03-4000	MSB-7272				
DESCRIPTION OF ARTICLES OR SERVICE					
Please charge deposit account number 03-4000 the \$130.00					
filing fees or any other filing fees for the following					
notice to file missing parts enclosed with this authorization.					
Title: Pituitary Adenylate	Cyclase Act	ivating Peptide (PACAP)			
Receptor 3 (R3) Agoi	nists and Th	eir Pharmacological			
Methods of Use					
Inventors: Clark Pan et al	•				
If additional space is needed attach separate sheet.					
WARNING: Information on this form no be included on this form. Provide creating the					
For prompt, accurate shipment please complete the follow	ving mailing label - please				
U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office		Melissa A. Shaw			
Washington, DC 20231	•	Bayer Corporation (name)			
OFFICIAL BUSINESS Return after five days		800 Dwight Way			
,		(street address) Berkeley, CA 94701			
MSB-7272 YOUR ORDER NUMBER		(city, state, zip code)			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, Washington, DC 20231.





United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

APPLICATION NUMBER FILING/RECEIPT DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NUMBER

09/671,773


09/27/2000

Clark Pan

MSB-7272

Melissa A Shaw Patent Department Bayer Corporation 800 Dwight Way P Berkeley, CA 94701





FORMALITIES LETTER

OC000000005632832

Date Mailed: 12/21/2000

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is missing.
 A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 130.

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

02/09/2001 SDENBOB1 00000005 034000 09671773

01 FC:105 130.00 CH

Sector #



PATENT MSB-7272

RESPONSE TO NOTICE

FILING RECEIPT

TO FILE MISSING PARTS AND CORRECTION OF

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail on the date indicated below and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Ludiuma Legianole

January 30, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Pan et al.

Serial No.: 09/671,773

Filed: September 27, 2000

Title: Pituitary Adenylate Cyclase Activating

Peptide (PACAP) Receptor 3 (R3) Agonists and Their Pharmacological

Methods of Use

Attention: Box Missing Parts

Commissioner of Patents and Trademarks

Washington, D.C. 20231

Sir:

This is in response to the December 21, 2000 Notice to File Missing Parts of Nonprovisional Application. In addition, Applicant requests a correction of the title in the Filing Receipt, also mailed December 21, 2000, a copy is enclosed for your review. Please correct the word "phatmacological" to --pharmacological--.

Transmitted herewith for filing are the following:

- 1. Notice to File Missing Parts of Nonprovisional Application (Part 2).
- 2. An executed Declaration for Patent Application.

3. A Deposit Account Order Form authorizing payment of the filing fee from Deposit Account 03-4000. Please also charge any additional fees due or credit any overpayment.

Dated:	1/30/01	
Daceu.		

Respectfully submitted,

Melissa A. Shaw Reg. No. 38,301

Attorney for Applicants

(510) 705-7901



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspta.gov

APPLICATION NUMBER

FILING DATE

GRP ART UNIT

FIL FEE REC'D

ATTY.DOCKET.NO DRAWINGS

TOT CLAIMS

IND CLAIMS

09/671.773

09/27/2000

1641

1044

MSB-7272

31

Melissa A Shaw Patent Department **Bayer Corporation** 800 Dwight Way P O Box 1986 Berkeley, CA 94701



FILING RECEIPT

OC000000005632831*

Date Mailed: 12/21/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Clark Pan, residence, NOT PROVIDED; Manami Tsutsumi, residence, NOT PROVIDED; Armen B. Shanafelt, residence, NOT PROVIDED;

Continuing Data as Claimed by Applicant

Foreign Applications

If Required, Foreign Filing License Granted 12/20/2000

Title

Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their phatmacological methods of use

Pharmacologica1

Preliminary Class

435

Data entry by : DUNCAN, KIMBERELY

Team: OIPE

Date: 12/21/2000



LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 tle 37, Code of Federal Regulations, 5.11 & 5.15

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231